Project Grant P01AI181935
Award Date 5/26/26
Completion Date 4/30/31
Dollars Obligated $3.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Grant Award Summary Weill Medical College of Cornell University received a $254,249 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 1, 2026, through April 30, 2028. The project combines host-directed and pathogen-directed therapeutic approaches to develop novel treatments for Mycobacterium tuberculosis (MTB) infection by exploiting the contrasting ways MTB...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Weill Medical College of Cornell University a $2.94 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 23, 2025, with a completion date of June 30, 2029. This research initiative aims to advance understanding of resistance and tolerance mechanisms to nitroimidazole antibiotics (pretomanid and delamanid) in Mycobacterium tuberculosis, the...
- Federal Grant Award Summary Weill Medical College of Cornell University received a $211,875 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 20, 2026, with completion scheduled for January 31, 2028. The award supports research to develop and analyze conditional knockdown mutants of Mycobacterium tuberculosis (MTB) in C3HEB/FEJ mice, which exhibit human-like...
- Federal Project Grant Award Summary Award Details: The National Institute of Allergy and Infectious Diseases (NIAID) awarded Weill Medical College of Cornell University a Project Grant valued at $254,250 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award was obligated on August 7, 2025, with an ultimate completion date of July 31, 2027, and performance conducted in New York. Products and Services: The grant funds research to develop and test proteolysis-targeting...
- Federal Project Grant Award Summary Cornell University's Office of Sponsored Programs received a $746,602 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through July 31, 2030. The award supports investigator-initiated biomedical research to develop novel therapeutics for tuberculosis (TB) treatment by stimulating bacterial cyclic adenosine monophosphate...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Weill Medical College of Cornell University a $442,146 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, with an ultimate completion date of January 31, 2028. This research initiative will investigate salicylate-based drugs, specifically the principal metabolite of aspirin, as adjuvants to potentiate bedaquiline's anti-tuberculosis (TB) activity....
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Weill Medical College of Cornell University a Project Grant totaling $806,208.00 (Award Date: September 4, 2025; Completion Date: August 31, 2030) under the Allergy and Infectious Diseases Research program (CFDA 93.855). This project, titled "Spatial Omics to Understanding HBV Control in People with HIV Coinfection," advances research into hepatitis B virus (HBV) treatment...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Health Research, Inc.'s Wadsworth Center Division a $403,756 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 14, 2026, for completion by March 31, 2028. This award funds research to map the determinants of bedaquiline (BDQ) resistance in Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis. The primary deliverable is a...
- Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $743,651 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco, effective August 1, 2025, through July 31, 2030. The project focuses on developing and validating plasma cell-free RNA (cfRNA) biomarkers for tuberculosis diagnosis and treatment monitoring. The research team will conduct diagnostic...
- Federal Grant Award Summary Weill Medical College of Cornell University received a $149,389 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 11, 2025, through July 31, 2027. The award supports research aimed at isolating, characterizing, and understanding the persistence mechanisms of clonal CD4 T cell populations within the HIV reservoir in people living with HIV on...